Deepak Assudani

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

Rupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj et al. · Journal of Clinical Investigation · 2010 · 459 citations · Full text

Medicine, Immunology, Oncology +17

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Robert Landewé, Iain B. McInnes et al. · The Lancet · 2022 · 158 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Iain B. McInnes, Akihiko Asahina, Laura C. Coates et al. · The Lancet · 2022 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Arthur Kavanaugh, Joseph F. Merola, Georg Schett et al. · The Lancet · 2020 · 142 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +8

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Stanley Cohen, A. Alonso-Ruiz, Piotr Adrian Klimiuk et al. · Annals of the Rheumatic Diseases · 2018 · 112 citations · Full text

Life Sciences, Clinical Sciences, Immunology +11